University of Kentucky

UKnowledge
Pathology and Laboratory Medicine Faculty
Patents

Pathology and Laboratory Medicine

4-27-2010

Compositions and Methods Useful for Treating Circulatory and
Hypovolemic Shock
Peter R. Oeltgen
University of Kentucky, peter.oeltgen@uky.edu

Meera Govindaswami
University of Kentucky, meera.govindaswami@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/pathology_patents
Part of the Medical Pathology Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Oeltgen, Peter R. and Govindaswami, Meera, "Compositions and Methods Useful for Treating Circulatory
and Hypovolemic Shock" (2010). Pathology and Laboratory Medicine Faculty Patents. 1.
https://uknowledge.uky.edu/pathology_patents/1

This Patent is brought to you for free and open access by the Pathology and Laboratory Medicine at UKnowledge. It
has been accepted for inclusion in Pathology and Laboratory Medicine Faculty Patents by an authorized
administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

US007705119B1

(12) United States Patent
Oeltgen et a].
(54)

COMPOSITIONS AND METHODS USEFUL
FOR TREATING CIRCULATORY AND
HYPOVOLEMIC SHOCK

(75) Inventors: Peter R. Oeltgen, Frankfort, KY (US);
Meera Govindaswami, Lexington, KY

(Us)

(10) Patent N0.:
(45) Date of Patent:

US 7,705,119 B1
Apr. 27, 2010

Bolling, S.F., Schwartz, C.F., Oeltgen, P.R., Kilgore, K., Su, T-P
Opiods confer myocardial toleranct to ischemia: Interaction of delta

opioids agonists and antagonists. J Thorac Caradiovasc Surg. 122:
476-81, 2001.
Chien, S., Oeltgen, P.R., Diana, J .M., Salley, R., Su, T-P. Extension of
tissue survival time in multiogran block preparation using delta
opioid DADLE. J. Thorac Cardiovasc Surg, 107: 964-67, 1994.

Fryer, R.M., Hsu, A., Eels, J.T., Nagase, H., Gross, G.J. Opioid

(73) Assignee: University of Kentucky Research
Foundation, Lexington, KY (US)

Induce Second Window of Cardioprotection- potential role of
mitochondrial KATP channels, Circ Res. 84: 846-51, 1999.
Fryer, R.M., Wang,Y., Hsu, A.K., Gross, G.J. Essential activation of
PKC-8 in opioid-induced cardioprotection. Am J Physiol Heart Cir

(*)

Subject to any disclaimer, the term of this
patent is extended or adjusted under 35

Physio1.280:H1346-53, 2001.

U.S.C. 154(b) by 0 days.

Neuroprotective effects of opioid-like hibernation factors in cerebral
ischemia. FASEB J 17(5) A895, No. 579.10 (2003).
Govindaswami, M., Rodgers, J .R., Lesnaw, J ., Oeltgen, P.R. A cell
culture assay for delta opioids and opioid-like hibernation speci?c
factors (HSF). FASEB J. 16:(5)A852, No. 643.25, 2003.

Notice:

(21) App1.No.: 11/759,013
(22) Filed:

Jun. 6, 2007

Govindaswami, M., Sanchez, A., Bishop, P.D., Bruce, D.S., Oeltgen,

Related U.S. Application Data

(60) Provisional application No. 60/910,774, ?led on Apr.
9, 2007.
(51)

Int. Cl.
C07K 7/06
A61K 38/08
A61P 7/08
CO7H 21/04

(2006.01)
(2006.01)
(2006.01)
(2006.01)

(58)

Field of Classi?cation Search ..................... .. None

536/23.1; 930/21

See application ?le for complete search history.
References Cited
U.S. PATENT DOCUMENTS

6,177,407
6,294,519
6,316,411
6,380,164
6,544,950
6,645,938
6,875,742
6,900,178
6,967,192
7,060,792

B1
B1
B1
B1
B1
B2
B2
B2
B2
B2

8/1987 Hosobuchi et al.
4/1997 Heavner et al.
8/2000 Schultz et a1.

1/2001
9/2001
11/2001
4/2002
4/2003
11/2003
4/2005
5/2005
11/2005
6/2006

Rodgers et a1.
Oeltgen et al.
Oeltgen et al.
Oeltgen et al.
Oeltgen et al.
Oeltgen et al.
Oeltgen et al.
Oeltgen et al.
Oeltgen et al.
Oeltgen et al.

FOREIGN PATENT DOCUMENTS
WO

WO9956766

11th International Symposium. Berlin, Germany: Springer-Verlag
Publishers, pp. 377-384, 2000.

Husted, T.L., Lentch, A.B., Govindaswami, M., Oeltgen, P.R.,

Karck, M., Tanaka, S., Bolling, S.F., Su, T-P, Oeltgen, P.R., Haverich,
A. Myocardial protection by ischemic preconditioning and o opioid

U.S. Cl. ....................... .. 530/328; 514/15; 514/921;

4,684,624 A
5,618,785 A
6,103,722 A

P.R. Opioid-like hibernation factors provide protection to ischemic
myocardium. In Heldmaier G, Kingenspor M (eds: Life in the Cold:

Rudich, S.M. A delta-2 opioid agonist inhibits p38 MAPK and sup
presses activation of murine macrophages. J. Surg Research 28:45
49, 2005.

(52)

(56)

Govindaswami, M., Bishop, P.D., Kindy, M.S., Oeltgen, P.R.:

11/1999

OTHER PUBLICATIONS
Uebel et al, 1997. Proc Natl Acad Sci USA. 94: 8976-8981.*

recepter activation in the isolated working rat heart: J Thorac
Cardiovasc. Surg. 122: 986-92, 2001.

Kevelaitis, E., Peynet, J ., Mousa, C., Launay, J .M., Menaschep.
Opening of potassium channels: the common cardioprotective link
between preconditioning and natural hibernation? Circ. 99:3079-85,
1999.

Liang, B.T., Gross. G.J. Direct preconditioning of cardiac myocytes
via opioid receptors and KATP channels: Circ Res. 84: 1396-00,
1999.

(Continued)
Primary ExamineriBridget E Bunner
Assistant ExamineriZachary C Howard
(74) Attorney, Agent, or FirmiStites & Harbison PLLC;
Mandy Wilson Decker

(57)
ABSTRACT
Polypeptides, compositions, and methods for treating shock
are described. A isolated polypeptide, Deltorphin-E, can be

administered without concomitant ?uid resuscitation, before,
concurrently with, or after the onset of shock or the occur
rence of an event that creates a risk of shock. Deltorphin-E

can be administered in accordance with the method as part of
a preconditioning strategy, which reduces the extent of

ischemic injury. Deltorphin-E can be used in preparation for
planned ischemia or in a prophylactic manner in anticipation
of further ischemic events.

23 Claims, 10 Drawing Sheets

US 7,705,119 B1
Page 2
OTHER PUBLICATIONS

Smith-Sonneborn, J ., Gottsch, H., Cubin, E., Oeltgen, P.R., Thomas,

May?eld, K.P., D’Alecy, L.G. Delta-l opioid agonist acutely

P. Alternative strategy for stress tolerance: Opioids J. Gerontol:

increases hypoxic tolerance. J Pharmacol Exp Ther. 268: 683-88

Biolog Sci. 59Az433-40, 2004.

(1994).

Stefhano, G.B., Salzet, M., Hughes, T.K., Bil?nger, TV. 82 opioid

McBride, S M., Smith-Sonneborn, J ., Oeltgen, P, and Flynn, F.W.
Delta2 opioid receptor agonist facilitates mean arterial pressure
recovery after hemorrhage in conscious rats. Shock 23(3) 264-268,

receptor subtype on human vascular endothelium uncouples mor
phine stimulated nitric oxide release. International J Cardiol. 64:S43

2005.

Oeltgen P.R., Govindaswami M., Witzke D.B. 24-hour pretreatment
With delta opioid enhances survival from hemorrhagic shock. Acad

Emerg Med. l3(2):l27-33, 2006.
Oeltgen, PR, Nilekani, S., Nuchols, P., Spurrier, W.A., Su T-P Fur
ther studies on opioids and hibernation: Delta opioid receptor ligand

51, 1998.
Summer, R.L ., Zizhuang, L., Hildebrandt, D.: Effect of a Delta recep

tor agonist on duration of survival during hemorrhagic shock. Acad

Emerg Med. 10:587-93, 2003.
Wild, K.D., T. Vanderah, H.I. Mosberg, and F. Porreca: Opioid d
receptor subtypes are associated With different potassium channels.

selectively induced hibernation in summer-active ground squirrels.

Eur. J. Pharmacol. 193: 135-136, 1991.

Life Sciences 43:l565-74, 1988.

Yellon, D.M., Bazxter, G.A. “second Window of protection” or

Patel, H.H., Hsu, A.K., Peart, J.N., Gross, G.J. Sarcolemmal KATP

delayed preconditioning phenomenon:

channel triggers opioid-induced delayed cardioprotection: Circ

myocardial protection. J Mol Cell Cardiol. 27:1023-34, 1995.
Zhang, J., Haddad, Xia. Y. Delta-, but not mu-and kappa-opioid
receptor activation protects neocortical neurons from glutamate-in
duced excitotoxic injury. Brain Res. 885: 143-53 (2000).

Research 91: 186-188, 2002.

Schultz, J.E., Hsu, A.K., Gross, G.J. Morphine mimics the
cardioprotection effect of ischemic preconditioning via
glibenclamide-sensitive mechanism in the rat heart. Cir Res 78: l 100

04, 1996.
Schultz, J.E. Hsu, A.K., Gross, G.J. Ischemic preconditioning and

future horizons for

Bell, S.P., Sac, M.N., Patel, A., Opie, L.H., Yellon, D.M. 8-Opioid
receptor stimulation mimics ischemic preconditioning in human

morphine-induced cardioprotection involve the delta-opioid receptor

heart muscle. J. Am Coll Cardiol. 36:2296-02, 2000.

in the intact rat heart. J Mol Cell Cardio. 29:2187-95, (1997).

Murakawa, K., Hirose, N., Takada, K., Suzuki, T., Nagase, H., Cools,

Schultz, J., Hzu, A., Nasase, H., Gross, G.J. TAN-67, a 8l-opioid
receptor agonist reduces infarct size via activation of G i/o proteins
and KATP channels. Am J Physiol. 274: H909-l4, 1998.

A., Koshikawa, N. Deltorphin II enhances extracellular levels of
dopamine in the nucleus accumbens via opioid receptor-independent
mechanisms. European J. of Pharm. 491: 31-36, 2004.

Schultz., J.E., Rose E.,Yao, Z., Gross, G.J. Evidence for involvement
of opiod receptors in ischemic preconditioning in rat hearts.. Am J

treatrnent With the novel deltorphin e, a 8-opioid receptor agonist,

Physiol. 268 (H2) 157-162, 1995.
Sigg, D.C., Coles, J. A., Oeltgen, P.R., Iaizzo, P.A. Role of delta

behaving rats. Shock, 2007.

Rutten, M., Govindaswami, M., Oeltgen, P., Smith-Sonneborn. Post
increases recovery and survival after severe hemorrhagic shock in

opioid receptor agonists on infarct size reduction in swine. Am J

Physiol Heart Circ Physiol. 282 (Hl) 953-60, 2002.

* cited by examiner

US. Patent

Apr. 27, 2010

59 i

Sheet 1 0f 10

US 7,705,119 B1

—o—-sa|ine

2.9 mg/kg DeIt-E
+4.2 mg/kg DeIt-E
+5.5 mg/kg DeIt-E

(mmHg)MAP
I\)(.0 Q)

.5‘

\

""lri

19*

9

EOH

\

\

20

\

\

40

\

60

80 100 120 140 160 180 200 220 240 260 280 300 320

Post Hemorrhage Period (min)

Figure 1.

US. Patent

Apr. 27, 2010

Sheet 2 0110

US 7,705,119 B1

Survival Time (min)
400

i

350 i

El Saline

55 mg/kg

El 2.9 mg/kg DeIt-E
300 i

I 4.2 mg/kg DeIt-E

I 5.5 mg/kg DeIt-E
250

i

200

i

150 i

2.9 mg/kg**

100 -

T

Saline
50 i

0 1

Figure 2.

4.2 mg/kg**

T

US. Patent

Apr. 27, 2010

Sheet 3 0f 10

US 7,705,119 B1

—¢—sa|ine

+5.5 mg/kg DeIt-E

GHRain

1O

30

40

MAP (mmHg)

Figure 3.

50

80

US. Patent

Apr. 27, 2010

Sheet 4 0110

US 7,705,119 B1

10 i

9

—Q—sa|ine
’

2.9 mg/kg DeIt-E

8 ’

+4.2 mg/kg DeIt-E

—I—5.5 mg/kg DeIt-E
7
2

6 i

_o
E
i

5 i

E
2
3 i

2
1

2

0

BOH

BOH
EOH

Figure 4.

EOH

Saline

2.9 mg/kg Delt-E

4.2 mg/kg Delt-E

5.5 mg/kg DeIt-E

1.55 i 0.11
8.88 i 0.12

1.54 i 0.20
8.1 i 0.76

1.51 i 0.21
7.5 i 0.29

1.54 i 0.26
6.54 i 1.3

US. Patent

Apr. 27, 2010

Sheet 5 0110

US 7,705,119 B1

50 *

49 48 4

5.5 mg/kg**
El saline

El 2.9 mg/kg DeIt-E

PHrueslge)(m

47 i

I 4.2 mg/kg DeIt-E

46 *

I 5.5 mg/kg DeIt-E

45 5

4.2 mg/kg**

44 i

2.9 mg/kg**

43*

T

42*
41 i

40*
39*

saline

38*
37*
36
saline

2.9 mg/kg Delt-E

4.2 mg/kg Delt-E

5.5 mg/kg Delt-E

38.27 i 0.44

42.23 i 0.37

43.65 i 0.40

47.94 i 0.55

Figure 5.

US. Patent

Apr. 27, 2010

Sheet 6 0110

US 7,705,119 B1

pH versus Survival Time
350 i

y = —124.78X + 1148.3
R2 = 0.9692

Nw00-\

01O O

i

(tsumirv neal)

6

6.5

7

7.5

pH
Figure 6.

8

8.5

9

US. Patent

160 *

Apr. 27, 2010

Sheet 7 0110

US 7,705,119 B1

“HQ-“Control

mum Deltorph in-E

(PAMretsaAuinPl)

80’
O? O

1

.5 O
NO

1

O

l

BOH

EOH

3O

l

l

6O

90

120

Minutes

Figure 7.

150

180

l

l

210

240

US. Patent

Apr. 27, 2010

500 i

Sheet 8 0110

US 7,705,119 B1

"'9'- Control
M" Deltorphin-E

Ft2EumH:MBV
100 i

50*

BOH

Figure 8.

EOH

3O

90
120
Minutes

150

180

210

240

US. Patent

Apr. 27, 2010

Sheet 9 0110

US 7,705,119 B1

?ue-“Control
120 —

D e | to rp h i n - E

100 —

20*

BOH EOH

30

60

90

120

Minutes

Figure 9.

150

180

210

240

US. Patent

Apr. 27, 2010

.

12 *

Sheet 10 0110

US 7,705,119 B1

Control

Deltorphin-E

(lLmaecvtoleL)
BOH

Figure 10.

EOH

US 7,705,119 B1
1

2

COMPOSITIONS AND METHODS USEFUL
FOR TREATING CIRCULATORY AND
HYPOVOLEMIC SHOCK

bleeding, hemodilutes the patient, and sets the stage for hypo
thermia, acidosis, and coagulopathy. This syndrome is par
ticularly problematic in patients With blunt trauma, Who often
have sources of bleeding that are not amenable to direct

control. Failure to resuscitate these patients Will, hoWever,
ultimately lead to irreversible shock. As such, currently used
resuscitation strategies can actually exacerbate ischemic

RELATED APPLICATIONS

This application claims priority from US. Provisional
Application Ser. No. 60/910,774 ?led Apr. 9, 2007, the entire
disclosure of Which is incorporated herein by this reference.

injury.
Third, although crystalloid resuscitation is ef?cacious in
most patients, it produces problematic tissue edema in

GOVERNMENT INTEREST

patients Who arrive to an ICU in severe shock. These patients
typically need massive ?uid resuscitation to maintain intra

This invention Was made, in part, With government support
from the US Of?ce of Naval Research (ONR) “Opioid-like

vascular volume and many develop abdominal compartment
syndrome, Which creates increased risks for multiple organ

Hibernation Factors Provide Cerebral Ischemic Protection”

failure. Patients With severe torso trauma Who are admitted
With shock and an associated severe closed head injury are in

(Account No. 4-6431). The government has certain rights in
the invention.

a precarious situation. Under-resuscitation decreases cerebral
BACKGROUND
20

Circulatory shock and hypovolemic shock are commonly
occurring threatening pathophysiological states, Which can
occur secondary to trauma, hemorrhage, burns, sepsis, aller
gic reactions, and heart failure. Shock-like microcirculatory
abnormalities are also associated With certain procedures,

perfusion pressure, Which causes secondary brain injury.
Excessive crystalloid administration promotes cerebral
edema, Which increases intracranial pressure and further
decrease cerebral perfusion pressure. As such, currently used
resuscitation strategies can exacerbate injury.
Fourth, shock initiates dysfunctional in?ammation that
causes multiple organ failure. Resuscitation is an obligatory

25

such as surgical procedures. Such shock, Whether systemic or
localiZed, is characterized by a reduction in blood pressure,

intervention to decrease the severity of the shock insult, but
current strategy is not directed at modulating in?ammation, in
fact, it may Worsen it. Laboratory studies shoW that lactated

blood ?oW, and/or blood volume, and can cause an insu?i

Ringer’s solution activates neutrophils. Even more disturbing

cient supply of blood and oxygen to vital organs and tissues.

is an observation that blood transfusion contains proin?am

This insuf?cient blood and oxygen supply can cause local
hypoxia, ischemia, and can lead to loss of cellular and organ
function and even death.

30

injury.

Currently-available treatments for circulatory and hypov
olemic shock include forms of volume infusion. For example,
the standard of care in initial management of hemorrhagic

matory mediators that both prime and activate neutrophils. As
such, currently used resuscitation strategies can exacerbate
Prospective randomiZed controlled trials studying cur

rently-used resuscitation strategies (crystalloid and colloid

shock is rapid administration of large volumes ?uids, several

resuscitation) Were conducted in the 1970s and 1980s, before
the recognition of abdominal compartment syndrome as an

liters in an adult patient. A preferred ?uid is Ringer’ s lactate,
although normal saline or other similar isotonic crystalloid

important clinical entity. Additionally, albumin Was the prin

solutions are also used. The standard continued treatment is
based on an observed response to the initial ?uid therapy.

35

cipal colloid used, but other types of colloid, such as starches
and gelatins, are available and are noW being used in resus
40

Guidelines generally provide that up to 300 ml of electrolyte
solution is required for each 100 ml of blood lost (“three for

citation. Because of their higher molecular Weights, colloids
such as starches and gelatins are con?ned to the intravascular
space, and their infusion results in more e?icient plasma

one” rule). For blood losses up to 30% of circulation blood

volume expansion. In severe hemorrhagic shock, hoWever,

volume, crystalloid alone Will often su?ice; hoWever, With

the permeability of capillary membranes increases, alloWing

ongoing blood loss, or a more signi?cant hemorrhage, prompt
surgical intervention or blood therapy becomes necessary.
Over the last decade, this standard approach has been reex
amined, leading to the conclusion that changes are needed in
current resuscitation strategies used by ?rst responders to

45

trauma settings and by medical personnel in emergency

50

rooms (ER) and intensive care units (ICU). There are multiple

organ injury, it has not been established that such a bene?t
could result from their use.

It has also been proposed that resuscitation With albumin
induces renal failure and even impairs pulmonary function.
Similarly, hetastarch has been shoWn to induce renal dysfunc

reasons for this conclusion.

First, the clinical trajectory of patients Who develop mul

tion in patients With septic shock and in recipients of kidneys

tiple organ failure is set early in the resuscitation process (i.e.,
Within about 6 hr of an event that creates a risk of shock, such

colloids to enter the interstitial space, Which can then Worsen

edema and impair tissue oxygenation. Although it has been
suggested that these high-molecular-Weight agents could
plug capillary leaks that occur during neutrophil-mediated

55

from brain-dead donors. Hetastarch also has a limited role in
massive resuscitation because it causes a coagulopathy and

as an injury resulting in hemorrhaging). Many patients at high
risk require emergency surgery or interventional radiology,

hyperchloremic acidosis due to its high chloride content. A

and arrive in an ICU after this time WindoW. Although resus

neW hydroxyethyl starch (HES) preparation (e.g., HEX

citation efforts in the ICU can clearly modify the subsequent
clinical course for the patient, even highly re?ned and indi
vidually tailored resuscitation cannot reverse the dysfunc

TEND®) purportedly does not cause these adverse effects,
60

thought that colloids might reduce the incidence of abdomi
nal compartment syndrome, but this possible bene?t must be
Weighed against the potentially detrimental effects of colloids

tional response that has already occurred. As such, currently
used resuscitation strategies do not adequately limit the
incidence of multiple organ failure.

Second, although initial crystalloidvolume loading is valu
able in de?ning hemodynamic stability, to continue this pro
cess in the face of ongoing hemorrhaging promotes further

but has not been studied in massive resuscitation. It is noW

already reported.
65

Results of numerous studies indicate that HES administra
tion can lead to reduction in circulating factor VII and von

Willebrand factor levels, impairment of platelet function,

US 7,705,119 B1
3

4

prolongation of partial thromboplastin time and activated
partial thromboplastin time, and increase in bleeding compli
cations. Coagulopathy and hemorrhage associated With HES

e?ted most from HSD. This observation Was consistent With

talloid, hypertonic saline or HSD increases cerebral perfusion

are often encountered in cardiac surgery, a setting in Which

pressure, decreases intracranial pressure, and decreases brain

susceptibility to such complications is heightened by tran
sient acquired platelet dysfunction resulting from the proce

edema, in combined head injury and hemorrhagic shock. This

laboratory data shoWing that, compared With isotonic crys

?nding has led some authorities to recommend that hyper
tonic saline should replace mannitol in the management of
intracranial hypertension in patients With severe closed head
injury. The argument in favor of hypertonic saline is even
more compelling With the recent recognition that hypertonic
saline resuscitation decreases the in?ammatory response

dure. Thus, in cardiac surgery studies With albumin as the

control, HES has resulted in platelet depletion and dysfunc
tion, prothrombin time and activated partial thromboplastin
time prolongation, and increased postoperative bleeding.
Dextran, as compared With albumin, has been shoWn to
reduce platelets and increase postoperative bleeding in car
diac surgery patients. Postoperative blood loss Was early cor
related With the volume of gelatin used to prime the extracor

(speci?cally neutrophil cytotoxicity) in animal models of
hemorrhagic shock, ischemia and reperfusion, and sepsis.
More recent studies have compared hypotensive and nor

motensive resuscitation of hemorrhage using lactated Ring
er’s (LR) With hypotensive resuscitation using HEXTEND®

poreal circuit. Arti?cial colloids, including dextran,
hetastarch and pentastarch, have been associated With renal
impairment, and HES has been demonstrated to increase sen

(Hex) 6% hetastarch in isotonic buffered saline in a multi

sitive markers of renal tubule damage in surgical patients. In
a study of sepsis patients, HES exposure Was recently shoWn

hemorrhage sheep model. Hypotensive resuscitation With LR

to be an independent risk factor for acute renal failure. In the

20

renal transplantation setting, HES has been found to reduce

urinary output, increase creatinine levels and dopamine
requirement, and increase the need for hemodialysis or hemo
dia?ltration.
Studies have suggested that both over- and under-resusci
tation can increase mortality. Early aggressive ?uid resusci

ues and loW levels of urinary ?oW in some animals in both
hypotensive treatment protocols and the occurrence of deaths

only in the hypotensive treatment protocols suggest that
25

resuscitation to a target MAP of 65 mmHg may be too loW for

optimal outcomes. Hypotensive resuscitation regimens may

tation can be deleterious, according to a clinical trail in Which

mortality Was reduced by delaying ?uid therapy. Also, there
are several practical and logistic limitations to the current

methods of prehospital resuscitation, Which include limita

greatly reduced volume requirements as compared With nor
motensive resuscitation, and Hex achieved additional volume
sparing. HoWever, trends toWard loWer base excess (BE) val

30

tions on the amount of ?uid that can be delivered due to

inadequate i.v. bore size and limited availability of ?uid in the

reduce bleeding but do not optimally restore metabolic func
tion.
To summarize, currently-available treatments for circula
tory and hypovolemic shock focus on various forms of vol
ume infusion. Intravenous ?uids appear to improve hemody
namic indices in the short term, but most also have adverse

?eld, e. g. combat casualty care. Hypotensive resuscitation is

consequences on hemostatic mechanisms. Indeed, it is noW

one approach that has been advocated as a better means to

becoming clear that resuscitation ?uids may actually poten

perform ?eld resuscitation of penetrating trauma. HoWever,
early application of aggressive resuscitation has been shoWn

35

to affect outcomes deleteriously in animal models of uncon

trolled hemorrhage, in Which aggressive resuscitation using a
variety of ?uids caused rapid increases in blood pressure,

internal bleeding, and higher mortality.

tional coagulopathy and secondary clot disruption from
40

In the early 1980s research interest in hypertonic saline Was
spurred. Small-volume hypertonic saline Was shoWn to be as

effective as large-volume crystalloids in expanding plasma
volume and enhancing cardiac output in hemorrhagic shock
in animals. Furthermore, hypertonic saline increased perfu
sion of the microcirculation, presumably by selective arteri
olar vasodilation and by decreasing sWelling of red blood
cells and of the endothelium. This improved microcircula
tion, hoWever, could lead to increased bleeding. Conse
quently, hypertonic saline Was tested in animal models of

Accordingly, there remains a need in the art for a method of

45

SUMMARY
The present invention meets some or all of the above
50

bleeding, but mortality Was model-dependent and the best
survival Was obtained When saline Was given With high-vol

Were done. Individually, these trials found survival outcome
to be inconsistently improved, but did document that a bolus
of hypertonic saline or HSD Was safe. Meta-analysis of these
data suggests that hypertonic saline is no better than standard
of care isotonic crystalloid ?uids, but that HSD might be

identi?ed needs, as Will become evident to those of ordinary
skill in the art after a study of information provided in this
document. This Summary describes several embodiments of
the presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This

Summary is merely exemplary of the numerous and varied
55

embodiments. Mention of one or more representative features

of a given embodiment is likeWise exemplary. Such an
embodiment can typically exist With or Without the feature(s)
mentioned; likeWise, those features can be applied to other

of the small volume needed to achieve these effects, there Was
great interest in the use of these ?uids in resuscitation in the
?eld for both military and civilian use.

From the late 1980s through the early 1990s, several trials

increased blood ?oW, increased perfusion pressure, and
decreased blood viscosity.

treating circulatory and hypovolemic shock, Which avoids the
above-identi?ed problems.

uncontrolled hemorrhagic shock and Was shoWn to increase

ume crystalloids. Additionally, the resuscitative effectiveness
of hypertonic saline Was found to be enhanced by combina
tion With dextran (hypertonic saline dextran (HSD)). In vieW

tiate cellular injury via severe immune activation and upregu
lation of cellular injury markers that can result in exacerba
tion of blood loss. Bleeding can also be enhanced by
injudicious ?uid administration as a consequence of dilu

embodiments of the presently-disclosed subject matter,
60

Whether listed in this Summary or not. To avoid excessive

repetition, this Summary does not list or suggest all possible
combinations of such features.
The present invention relates to the use of an isolated

polypeptide, compositions and methods for treating shock

better. Subgroup analysis shoWed that patients Who presented

associated With a reduction of blood volume, or an insu?i
cient supply of blood to an organ or tissue. The method alloWs

With shock and concomitant severe closed head injury ben

bleeding to be controlled, While providing effective hemody

65
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namic and metabolic support. The method can be practiced
Without making use of resuscitation ?uids, Which have been
associated With various disadvantages and risks. The method
of the present invention can be used for treating shock that is
characterized by a state of Whole body ischemia. The method
of the present invention can be used for treating circulatory

FIG. 2 is a bar graph comparing the time of survival for
Delt-E-treated groups at three different doses and control
group, Where treatment Was immediately after severe hemor

rhage.
FIG. 3 is a graph of the average heart rate gain post-severe
hemorrhage after treatment With saline or 5.5 mg/kg Delt-E.
FIG. 4 is a graph comparing lactate levels (mmol/l), in
arterial blood sampled at the beginning and end of hemor
rhage for control group and Delt-E-treated groups at three

and hypervolemic shock, such as hemorrhagic shock, and
injuries resulting from such shock, such as injuries to an organ
or tissue due to an inadequate supply of oxygen being deliv

different doses Where treatment Was immediately after severe

ered to the organ or tissue.

hemorrhage.

Disclosed herein is an isolated polypeptide, comprising the
amino acid sequence Tyr-(D-Ala)-Phe-Ala-Ile-Gly-Asp
Phe-Ser-Ile-NH2 (SEQ ID NO: 1), Which is referred to herein

FIG. 5 is a bar graph comparing the Delt-E dose response

postinj ection pulse pressure (difference betWeen systolic and
diastolic pressure).

as Deltorphin-E or Delt-E. Amino acids can occur in tWo

FIG. 6 is a graph of the Delt-E dose response postinj ection
comparison of pH versus survival time.
FIG. 7 is a graph comparing mean arterial pressure (MAP,

possible optical isomers, D isomers and L isomers. D-Ala
refers to a D-isomer of alanine. Also disclosed herein is a

biologically active Deltorphin-E polypeptide, including an
amino acid sequence having at least about 90% or greater
homology to SEQ ID NO: 1. Also disclosed herein is a bio

mmHg) as a function of time for Delt-E-treated and control
groups Where treatment Was prior to hemorrhage.
20

logically active Deltorphin-E polypeptide, including an
amino acid sequence encoded by a nucleic acid sequence
having at least about 90% or greater homology to the nucleic

acid sequence TAnl GCn3 TTnl GCn3 ATn2 GGn3 GAnl
TTnl AGnl ATn2 (SEQ ID NO: 2), Where n1 is T or C; n2 is T,

FIG. 9 is a graph comparing the percentage of survivors for
25

C, or A; and n3 is T, C, A, or G. Also disclosed herein are

effective amount of a Deltorphin-E polypeptide, and a phar
30

An exemplary method of the present invention includes
administering an effective amount of a Deltorphin-E

Where treatment Was prior to hemorrhage.

BRIEF DESCRIPTION OF THE SEQUENCE
LISTING

polypeptide in a pharmaceutically acceptable formulation.
The polypeptide can be administered concurrently With or
before the onset of shock or the occurrence of an event that 35

creates a risk of shock. The polypeptide can be administered
up to about 24 hours before the onset of shock or the occur
rence of the event. The polypeptide can be administered sub
sequent to the onset of shock or the occurrence of an event that
creates a risk of shock. The polypeptide can be administered
up to about 4 hours subsequent to the occurrence of an event
that creates a risk of shock.

Delt-E-treated and control groups as a function of time, Where
treatment Was prior to hemorrhage.

FIG. 10 is a graph comparing lactate levels (mmol/L) in
arterial blood samples at the beginning of hemorrhage and at
the end of hemorrhage for Delt-E-treated and control groups

pharmaceutical compositions, including a pharmaceutically

maceutically acceptable carrier.

FIG. 8 is a graph comparing average heart rates (HR,
beats/minute) as a function of time for Delt-E-treated and
control groups, Where treatment Was prior to hemorrhage.

SEQ ID NO: 1 is an isolated polypeptide Deltorphin-E

(Delt-E), including the folloWing amino acid sequence: Tyr

(D-Ala)-Phe-Ala-Ile-Gly-Asp-Phe-Ser-Ile-NH2.
SEQ ID NO: 2 is an isolated nucleic acid molecule, includ
40

ing the folloWing nucleic acid sequence: TAnl GCn3 TTnl
GCn3 ATn2 GGn3 GAnl TTnl AGnl ATn2, Where n1 is T or C;
n2 is T, C, orA; and n3 is T, C, A, or G.
DESCRIPTION OF EMBODIMENTS OF THE
INVENTION

The event creating a risk of shock can be, for example,
hemorrhage or a planned surgery. Examples of planned sur

geries include planned ischemia, heart valve replacement
surgery, coronary artery bypass graft surgery, stint placement

The details of one or more embodiments of the present
invention are set forth in this document. Modi?cations to

surgery, orthopedic surgery, organ repair surgery, organ trans plantation surgery, and a surgery to implant a device.
An effective amount of the polypeptide can be adminis
tered in accordance With an exemplary method such that one

embodiments described in this document, and other embodi
ments, Will be evident to those of ordinary skill in the art after
a study of the information provided in this document. The

50

a prophylactic effect. A desired effect can be a therapeutic

information provided in this document, and particularly the
speci?c details of the described exemplary embodiments, is
provided primarily for clearness of understanding and no

effect. In certain embodiments, treatment using the polypep

unnecessary limitations are to be understood therefrom. In

tide can produce one or more prophylactic effects and one or 55

case of con?ict, the speci?cation of this document, including
de?nitions, Will control.

or more desired effects are produced. A desired effect can be

more therapeutic effects. Examples of prophylactic effects
include preventing or reducing the risk of shock, and prevent
ing or reducing the risk of injuries resulting from shock.
Examples of therapeutic effects include curing or mitigating
shock, and restoring perfusion to organs and tissues.

While the folloWing terms are believed to be Well under

stood by one of ordinary skill in the art, the folloWing de?ni
60

DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph comparing dose-dependent recovery of
mean arterial pressure (MAP, mmHg) as a function of time for
Delt-E-treated groups and control group, Where treatment
Was immediately after severe hemorrhage.

65

tions are set forth to facilitate explanation of the present
invention.
Unless de?ned otherWise, all technical and scienti?c terms
used herein have the same meaning as commonly understood

by one of ordinary skill in the art. Although any methods,
devices, and materials similar or equivalent to those described
herein can be used in the practice or testing of the presently

disclosed subject matter, representative methods, devices,
and materials are noW described.
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Unless otherwise indicated, all numbers expressing quan
tities of ingredients, properties such as reaction conditions,

have been conservatively substituted With a functionally

similar residue, and Which is biologically active. The phrase
“conservatively-substituted variant” also includes polypep

and so forth used in the speci?cation and claims are to be

understood as being modi?ed in all instances by the term
“about”. Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this speci?cation and claims
are approximations that can vary depending upon the desired

tides Wherein a residue is replaced With a chemically-deriva

tiZed residue, provided that the resulting polypeptide is bio
logically active. Examples of conservative substitutions
include the substitution of one non-polar (hydrophobic) resi
due, such as isoleucine, valine, leucine, or methionine for
another; the substitution of one polar (hydrophilic) residue
for another, such as betWeen arginine and lysine, betWeen

properties sought to be obtained by the presently-disclosed
subject matter.
As used herein, the term “about,” When referring to a value
or to an amount of mass, Weight, time, volume, concentration

glutamine and asparagine, betWeen glycine and serine; the
substitution of one basic residue such as lysine, arginine, or
histidine for another; or the substitution of one acidic residue,
such as aspartic acid or glutamic acid for another.
The term “isolated”, Whenused in the context of an isolated

or percentage is meant to encompass variations of in some

embodiments 120%, in some embodiments 110%, in some
embodiments 15%, in some embodiments 11%, in some
embodiments 10.5%, and in some embodiments 10.1% from
the speci?ed amount, as such variations are appropriate to

polypeptide, is a polypeptide that, by the hand of man, exists

perform the disclosed method.
As used herein, the term “biologically active” refers to an
ability to affect treatment for the disease state being treated
When provided in an effective amount.
As used herein, the terms “effective amount” and “thera
peutically effective amount” are used interchangeably and
mean a dosage su?icient to provide treatment for the disease
state being treated. The exact amount that is required Will vary

from subject to subject, depending on the species, age, and
general condition of the subject, the particular carrier or adju
vant being used, mode of administration, and the like. As
such, the effective amount Will vary based on the particular
circumstances, and an appropriate effective amount can be
determined in a particular case by one of ordinary skill in the

apart from its native environment and is therefore not a prod
uct of nature. An isolated polypeptide can exist in a puri?ed
form or can exist in a non-native environment such as, for
20

example, in a transgenic host cell.
Disclosed herein are polypeptides, compositions, and
methods useful for treating shock associated With a reduction
of blood volume, or an insuf?cient supply of bloodto an organ

or tissue. For example, the compositions and methods of the
25

present invention may be used for treating circulatory and
hypovolemic shock, such as hemorrhagic shock, and injuries
resulting from such shock, such as injuries to an organ or

tissue due to an inadequate supply of oxygen being delivered
to the organ or tissue.
30

The present invention includes an isolated Deltorphin-E

art using only routine experimentation.

(Delt-E) polypeptide, comprising the amino acid sequence

The term “nucleic acid” refers to deoxyribonucleotides or
ribonucleotides and polymers thereof in either single- or
double-stranded form. Unless speci?cally limited, the term
encompasses nucleic acids containing knoWn analogues of
natural nucleotides that have similar binding properties as the

ID NO: 1). Amino acids can occur in tWo possible optical
isomers, D isomers and L isomers. D-Ala refers to a D-isomer
of alanine. In certain embodiments, Delt-E has a molecular
Weight of about 1102.3 daltons. In certain embodiments, a

Tyr-(D-Ala)-Phe-Ala-lle-Gly-Asp-Phe-Ser-lle-NH2 (SEQ
35

reference nucleic acid and are metaboliZed in a manner simi

biologically active Deltorphin-E polypeptide includes an

lar to naturally occurring nucleotides. Unless otherWise indi
cated, a particular nucleic acid sequence also implicitly
encompasses conservatively modi?ed variants thereof (e.g.,

amino acid sequence having at least about 90% or greater
homology to SEQ ID NO: 1. In certain embodiments, a bio
40

degenerate codon substitutions) and complementary
sequences and as Well as the sequence explicitly indicated.

Speci?cally, degenerate codon substitutions can be achieved
by generating sequences in Which the third position of one or
more selected (or all) codons is substituted With mixed-base

logically active Deltorphin-E polypeptide includes an amino
acid sequence encoded by a nucleic acid sequence having at
least about 90% or greater homology to the nucleic acid

sequence TAnl GCn3 TTnl GCn3 ATn2 GGn3 GAnl TTnl
45

and/or deoxyinosine residues (BatZer et al. (1991) Nucleic

AGnl ATn2 (SEQ ID NO: 2), Where n1 is T or C; 112 is T, C, or
A; and n3 is T, C, A, or G. The Deltorphin-E polypeptide can
be produced by a number of methods known to those skilled
in the art, such as methods using an automated peptide syn
thesiZer or through recombinant molecular biology tech

Acid Res 1915081; Ohtsuka et al. (1985) JBiol Chem 260:

2605-2608; Rossolini et al. (1 994) Mol Cell Probes 8:91-98).

niques.

The terms “nucleic acid” or “nucleic acid sequence” can also

be used interchangeably With gene, open reading frame
(ORF), cDNA, and mRNA encoded by a gene.
As used herein, the term “polypeptide” means any polymer
comprising any of the 20 protein amino acids, regardless of its
siZe. Although “protein” is often used in reference to rela

50

tively large polypeptides, and “peptide” is often used in ref

55

The present invention includes compositions comprising a
pharmaceutically effective amount of a Deltorphin-E

polypeptide, and a pharmaceutically acceptable carrier.
Exemplary compositions can include a pharmaceutically
acceptable carrier. Suitable formulations include aqueous and
non-aqueous sterile injection solutions that can contain anti

erence to small polypeptides, usage of these terms in the art

oxidants, buffers, bacteriostats, bactericidal antibiotics and

overlaps and varies. The term “polypeptide” as used herein

referring to a gene product. Unless otherWise indicated, a

solutes that render the formulation isotonic With the bodily
?uids of the intended recipient; and aqueous and non-aqueous
sterile suspensions, Which can include suspending agents and
thickening agents. The compositions can take such forms as
suspensions, solutions or emulsions in oily or aqueous

particular polypeptide also implicitly encompasses conserva
tively-substituted variants thereof.

pending, stabiliZing and/or dispersing agents. Alternatively,

refers to peptides, polypeptides and proteins, unless other
Wise noted. As used herein, the terms “protein,” “polypep
tide,” and “peptide” are used interchangeably herein When

60

vehicles, and can contain formulatory agents such as sus

Delt-E can be in poWder form for constitution With a suitable

The term “conservatively substituted variant” refers to a

polypeptide comprising an amino acid residue sequence sub
stantially identical to the sequence of a polypeptide Whose
sequence is disclosed herein, in Which one or more residues

65

vehicle before use.

The formulations can be presented in unit-dose or multi

dose containers, for example sealed ampoules and vials, and
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including, but not limited to, domesticated sWine, ruminants,
ungulates, horses (including race horses), poultry, and the

can be stored in a frozen or freeZe-dried (lyophiliZed) condi

tion requiring only the addition of sterile liquid carrier imme

like.
Treatment can be affected in accordance With the present
invention before, concurrently With, or after an event that

diately prior to use.
In certain embodiments, Delt-E can be formulated for
administration in an aqueous-based liquid, such as phos
phate-buffered saline, to form an emulsion. For example,
Delt-E can be solubiliZed in a solution including ethanol,
propylene glycol, and 1N NaOH in a 1:111 ratio, or formu
lated in an organic liquid such as hydroxy-propyl-beta-cyclo

creates a risk of shock, such as hemorrhage. Treatment can be

affected in accordance With the present invention before,
concurrently With, or after the shock occurs. Desired effects
of treatment can include therapeutic effects and prophylactic
effects.
For example, if the treatment is affected before the event

dextrin to form a solution. An appropriate amount of Delt-E

can be solubiliZed in about 100 pl of the ethanol/propylene
glycol/NaOH solution or hydroxy-propyl-beta-cyclodextrin.
A desired concentration of Delt-E can be obtained by adding

creating a risk of shock occurs, the treatment can be intended

to produce prophylactic effects. For another example, if the
treatment is affected concurrently With or after the event
creating a risk of shock occurs, the treatment can also be

sterile physiological saline, phosphate buffered saline, or lac
tated Ringer’s solution. The initial alkaline pH can be

adjusted to a desired pH using, for example, 1N HCl. The pH

intended to produce prophylactic effects. In such cases, treat
ment could be intended to prevent or reduce the risk of shock,

can be adjusted to betWeen about 7.35 and about 7.45, or
about 7.4.

and/or prevent or reduce the risk of injuries resulting from
such shock.

The present invention includes methods for treating shock

20

associated With a reduction of blood volume, or an insu?i

For another example, if the treatment is affected concur
rently With or after the shock occurs, the treatment can be

cient supply of blood to an organ or tissue using Delt-E. For
example, states of Whole body ischemia, as occurs in hemor

intended to produce prophylactic and therapeutic effects, pre
venting or reducing injuries resulting from shock, and curing

rhagic shock, can be treated using methods of the present
invention. For another example, methods of the present inven
tion can be used to provide extended pharmacological

and perfusion of organs and tissues.

or mitigating the shock, e. g., restoring mean arterial pressure
The methods of the present invention can make use of

Delt-E and compositions containing Delt-E, and are useful in
a variety of settings. For example, Delt-E treatment is useful

ischemic preconditioning (PPC) in hemorrhagic shock. The
methods can be practiced Without the use of volume infusion

(i.e., Without the use of resuscitation ?uids).
For purposes of simplicity, When the term “shock” is used
herein, unless otherWise indicated, it is used to describe cir

30

in clinical settings Where planned surgeries are performed,
including planned ischemia and other procedures. In this
regard, it can be desirable to treat a subject Who Will undergo
a planned ischemia or surgical procedure, prior to the occur
rence of the procedure, because such procedures can result in

culatory or ischemic shock, hypervolemic shock, hemor
rhagic shock, or other types of shock associated With a reduc

hemorrhage, ischemia, and/or shock, i.e., affecting treatment

tion of blood volume in an organ or tissue, or an insuf?cient 35 before an event that creates a risk of shock using Delt-E as a
supply of blood to an organ or tissue.

pharmacological ischemic preconditioning agent Where

Shock that can be treated in accordance With the present

ischemic events can be anticipated. Depending on the status

invention can occur in a number of situations. For example, an
event that creates a risk of shock can occur in civilian and

of a subject undergoing a procedure, medical personnel could
treat that subject after the procedure has been initiated, for
example, When a risk of hemorrhage becomes apparent. For

military trauma settings, such as hemorrhage creating a risk

40

of hemorrhagic shock. For another example, an event such as
a planned surgery can create a risk of shock. Examples of such

another example, Delt-E treatment is useful in an emergency
room (ER) or an intensive care unit (ICU) setting. For another
example, Delt-E treatment is useful in civilian trauma set

surgeries include, heart valve replacement surgeries, coro

nary artery bypass graft surgeries, stint placement surgeries,
orthopedic surgeries, organ repair surgeries, organ transplan

tings, e.g., highWay accident scenes, or military trauma set
45

tings. In this regard, Delt-E could be rapidly administered by
?rst responders during the initial period folloWing trauma,

tation surgeries, surgeries to implant devices, and the like.
An exemplary method of the present invention for treating

When lifesaving intervention is often considered most critical.

shock in a subject includes administering an effective amount

Depending on the status of a subject being treated in a trauma

of Delt-E to the subject. As used herein, the term “subject”
includes both human and animal subjects. Thus, the disclosed
methods can have veterinary therapeutic uses. As such, the
presently disclosed subject matter provides for the treatment

50

setting, a ?rst responder could treat that subject before the
onset of shock, concurrently With the onset of shock, or after
the onset of shock. Since large volumes of resuscitation ?u
ids, Which are associated With knoWn methods of treatment,

of mammals such as humans, as Well as those mammals of

Would not be required When administering Delt-E, the

importance due to being endangered, such as Siberian tigers;

method of the present invention is especially useful in a
civilian or military trauma setting, Where large ?uid volumes

of economic importance, such as animals raised on farms for

55

consumption by humans; and/or animals of social importance

Would be dif?cult to obtain, transport, or access.
Delt-E can be administered prior to the onset of shock or
prior to the occurrence of an event that creates a risk of shock,

to humans, such as animals kept as pets or in ZOOS. Examples
of such animals include but are not limited to: camivores such

as cats and dogs; sWine, including pigs, hogs, and Wild boars;
ruminants and/ or ungulates such as cattle, oxen, sheep,

e.g., planned surgery. For example, in some embodiments,
60

giraffes, deer, goats, bison, and camels; and horses. Also

Delt-E can be administered up to about 24 hours prior to the

provided is the treatment of birds, including the treatment of

onset of shock or prior to the occurrence of an event that
creates a risk of shock. In some embodiments, Delt-E can be

those kinds of birds that are endangered and/ or kept in Zoos,
as Well as foWl, and more particularly domesticated foWl, i.e.,

to the onset of shock or prior to the occurrence of an event that

poultry, such as turkeys, chickens, ducks, geese, guinea foWl,

administered up to about 1, 2, 3, 4, 5, 10, 15, or 20 hours prior

and the like, as they are also of economic importance to

creates a risk of shock. Further, in some embodiments, Delt-E
can be administered about 20 to about 24 hours prior to the

humans. Thus, also provided is the treatment of livestock,

onset of shock or prior to the occurrence of an event that
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creates a risk of shock. In some embodiments, Delt-E can be

ug/kg to about 1000 ug/kg, from about 1 mg/kg to about 2
mg/kg, from about 2 mg/kg to about 3 mg/kg, from about 3
mg/kg to about 5 mg/kg, from about 5 mg/kg to about 10
mg/kg, from about 10 mg/kg to about 15 mg/kg, and from
about 15 mg/kg to about 20 mg/kg.

administered about 15 to about 20 hours, about 10 to about 15
hours, about 5 to about 10 hours, about 4 to about 5 hours,
about 3 to about 4 hours, about 2 to about 3 hours, or about 1
to about 2 hours prior to the onset of shock or the occurrence
of an event that creates a risk of shock.
Delt-E can be administered up to about 4 hours subsequent

For additional guidance regarding formulation and dose,
see US. Pat. Nos. 5,326,902; 5,234,933; PCT International

Publication No. WO 93/25521; BerkoW et al., (1997) The
Merck Manual of Medical Information, Home ed. Merck
Research Laboratories, Whitehouse Station, N.J.; Goodman
et al., (1996) Goodman & Gilman's the Pharmacological
Basis of Therapeutics, 9th ed. McGraW-Hill Health Profes

to the onset of shock or the occurrence of an event that creates

a risk of shock. Delt-E can be administered up to about 1, 2,
or 3 hours subsequent to the onset of shock or the occurrence
of an event that creates a risk of shock. Delt-E can be admin
istered concurrently With the onset of shock or the occurrence
of an event that creates a risk of shock.

sions Division, NeW York; Ebadi, (1998) CRC Desk Refer

Delt-E can be administered in accordance With the present

ence of Clinical Pharmacology. CRC Press, Boca Raton,

invention in a variety of manners. A solution or an emulsion of
Delt-E can be administered parenterally. A solution or an

Fla.; KatZung, (2001) Basic & Clinical Pharmacology, 8th
ed. Lange Medical Books/McGraW-Hill Medical Pub. Divi

emulsion of Delt-E can be administered by intravenous inj ec

sion, NeW York; Remington et al., (1975) Remington's Phar

tion, intraperitoneal injection, or intraarterial inj ection. A

maceutical Sciences, 15th ed. Mack Pub. Co., Easton, Pa.;
and Speight et al., (1 997) Avery's Drug Treatment: A Guide to
the Properties Choice, Therapeutic Use and Economic Value
ofDrugs in Disease Management, 4th ed. Adis International,
Auckland/Philadelphia; Duch et al., (1998) Toxicol. Lett.

solution or an emulsion of Delt-E can be administered by

direct injection into the brain, for example, intracerebroven

20

tricular injection, for dispersion to other areas. Injection vol
umes can be about 0.5 to about 2.0 milliliters. Delt-E can be

administered in combination With other compounds, if
desired.
Actual dosage levels of Delt-E can be varied so as to
administer an amount of Delt-E that is effective to achieve the

100-101:255-263.

The present invention is further illustrated by the folloWing
25

speci?c but non-limiting examples. The folloWing examples
may include compilations of data that are representative of
data gathered at various times during the course of develop
ment and experimentation related to the present invention.

desired therapeutic response for a particular subject and/or
application. The selected dosage level Will depend upon a

variety of factors including the activity of the therapeutic
composition, formulation, the route of administration, com
bination With other drugs or treatments, severity of the con

30

EXAMPLES

dition being treated, the physical condition and prior medical

A murine hemorrhagic shock model Was used to evaluate

history of the subject being treated, and the like. Preferably, a

the effects of administration of Deltorphin-E (Delt-E), With

minimal dose is administered, and dose is escalated in the
absence of dose-limiting toxicity to a minimally effective
amount. Determination and adjustment of a therapeutically

35

Study Design: Post Hemorrhage Delt-E Infusion
The hemorrhagic shock model used Was a volume-con
trolled model similar to that of Summers et al. Acad Emerg

effective dose, as Well as evaluation of When and hoW to make

such adjustments, are knoWn to those of ordinary skill in the
art of medicine, and any necessary determinations in a par
ticular case can be made by those of ordinary skill in the art

out concomitant ?uid resuscitation, on hemodynamic status,
plasma lactate levels, and survival rates.

Med. 10:587-93 (2003). Forty-six male Sprague-DaWley rats
40

using only routine experimentation.
For administration of a composition as disclosed herein,

(about 341-41 1 grams) Were acclimated to a laboratory envi
ronment for a Week. In dWelling hepariniZed PE 10 catheters
Were placed in the femoral artery and the femoral vein of

conventional methods of extrapolating human dosage based

anesthetiZed rats. The tWo catheters Were combined and

on doses administered to a murine animal model can be

exited suprascapularly, tied in place With braided silk, and

carried out using the conversion factor for converting the
mouse dosage to human dosage: Dose Human per kgIDose

45

Mouse per kg><12 (Freireich et al., (1966) Cancer Chemother
Rep. 50:219-244). Drug doses can also be given in milligrams
per square meter of body surface area because this method,
rather than body Weight, achieves a good correlation to cer

50

surface area can be used as a common denominator for drug

(n:6), 2.85 mg/kg Delt-E (n:6), 4.2 mg/kg Delt-E (n:6), 5.5
mg/kg Delt-E (n:6), and 14 mg/kg Delt-E (n:6). Animals

dosage in adults and children as Well as in different animal
55
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about 1 ug/kg to about 20 mg/kg of body Weight of the subject
being treated. In certain embodiments of the invention, useful

by a 5.5 mg/kg injection of Delt-E.
Treatment: TWenty-four hours after catheter placement,
test rats (n:24) Were infused in the femoral vein With either

2.85, 4.2, 5.5 or 14 mg/kg of Delt-E (Tyr-D-Ala-Phe-Ala-Ile
Gly-Asp-Phe-Ser-Ile-NH2; SEQ ID NO: 1) dissolved in 1.0
ml Lactated Ringers (LR) solution pH 7.4. Control rats (n:6)

doses of Delt-E are from about 1-1000 ug/kg. In certain
embodiments of the invention, useful doses of Delt-E are:

from about 1 ug/kg to about 200 ug/kg, from about 200 ug/kg
to about 250 ug/kg, from about 250 ug/kg to about 500 ug/kg,
from about 500 ug/kg to about 750 ug/kg, from about 750

Were also selected and randomly assigned to 1 of 4, 30-minute
pre-treatment inhibitor groups: Naltriben Methane Sulfonate

(NTB) (n:4), Naltrexone (n:4), Glibenclamide (n:4), and
7-DehydrobenZylidine naltrexone (BNTX) (n:4) folloWed

m:3700 mg/m2.
In certain embodiments, useful doses of Delt-E are from

alloWed access to food and Water, and alloWed unrestricted
access to both catheters. The femoral artery catheter Was used
for volume-controlled hemorrhage and blood pressure mea
surements and the femoral vein catheter Was used for Delt-E

infusion. Each selected animal Was randomly assigned 1 of 6
post hemorrhage treat groups: 1 mL/100 g saline control

tain metabolic and excretionary functions. Moreover, body
species as described by Freireich et al. (Freireich et al., (1966)
Cancer Chemother Rep. 50:219-244). Brie?y, to express a
mg/kg dose in any given species as the equivalent mg/ sq m
dose, multiply the dose by the appropriate km factor. In an
adult human, 100 mg/kg is equivalent to 100 mg/kg><37 kg/ sq

covered With a piece of hypoallergenic mesh to prevent kink
ing. Rats Were then placed in recovery cages for 24 hr,
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Were infused With 1.0 ml Lactated Ringers solution pH 7.4.
Prior to hemorrhage MAP and HR Were recorded to establish

baseline levels. During hemorrhage approximately 48% of
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the total blood volume Was removed at a rate of 3 mL/ 100 g
over a 9- to 11-minute period. After the ?nal mL of blood Was

MAP recorded during recovery post hemorrhage Was signi?

removed the various venous catheter treatment injections
Were administered, MAP and HR Were recorded continu
ously for the duration of survival or up to 6 hours.

and 5 .5 mg/kg (P<0.01) treated Delt-E group versus the saline
control group, 50117 mmHg, 53111 mmHg, and 5817
mmHg vs. 3519 mmHg respectively. HoWever, mean heart

Biomarker protocols: Survival time Was determined by the
post hemorrhage time after injection until death, or a prede

rate trended doWnWard for both groups With no signi?cant
difference in heart rate betWeen the control group and any
Delt-E treated group.

cantly higher for 2.9 mg/kg (P<0.05), 4.2 mg/kg (P<0.05),

termined 360 minute survival interval. Death Was de?ned as

systolic blood pressure Without pulsation, and apnea. Ani
mals Were observed for several more minutes to ensure that

TABLE 1

autoresuscitation did not occur. Any animal surviving 360
Delt-E Dose Response Comparison of Hemodynamic Biomarkers.

minutes Was sacri?ced according to our protocol With ure

thane (1.0 g/kg, Sigma Aldrich). This Was done to minimiZe

Group (n)

Survival Time

Maximum MAP

Maximum HR

any discomfort to the animal and also because reportedly

(dose)

in minutes 1 S.E.

in mmHg 1 S.E.

in BPM 1 S.E.

35 1 9

425 1 94

107 111**

50 117*

432 1 79

232 114**

53 111*

403 1 65

331118**TT

58 1 7**

396 1 40

51 115*

394 1 79

D-Alanine deltrophins exhibit plasma half-lives of six hours
Saline (6)

(Marastoni et al. 1991). Plasma lactate levels Were deter

Delt-E (6)

(2.9 mgkg)

venous catheter injection utiliZing a Vitros® 950 Chemistry

AnalyZer (Ortho-Clinical Diagnostics, Rochester, N.Y.).

20

Pulse pressure Was determined by the difference (mmHg)
betWeen the systolic and diastolic pressure during a single
cardiac cycle. A total of six measurements for each treatment

Opioid Inhibitors: The opioid inhibitors (naltrexone, nal
triben methane sulfonate (NTB) and 7 DehydrobenZylidine
naltrexone (BNTX) and Glibenclamide Were administered 30
minutes prior to hemorrhage. MAP and HR Were recorded
continuously before hemorrhage to ensure no adverse affects

Delt-E (6)

25 J[*[Rats sacri?ced at six hours.
*P < 0.05 compared With saline controls
**P < 0.01 compared With saline controls.
(n) = number of animals per treatment group
Legend: MAP = mean arterial pressure and BPM = beats per minute.

Repeated-measures ANOVA revealed statistically signi?cant differences in
30 survival time distributions, and maximum MAP distributions between the

control and Delt-E groups. Post-Hoc measurements shoWed signi?cant
increase in survival time in both the 4.2 mg/kg and 5.5 mgkg Delt-E treated
groups. MAP Was also signi?cantly improved in both the 4.2 and 5.5 mgkg
Delt-E treated group. There Was no signi?cance difference seen in the Heart
Rate maximum BPM between any of test groups.

35

science) Were used as 30 minute pre-inj ection opioid receptor

antagonists. Glibenclamide (10 mg/kg, Sigma Aldrich) Was
used as a KATP channel blocker.
40

SPSS softWare With P value <0.05 being considered signi?
cant. The survival, MAP, HR and lactic acid values Were

analyZed using repeated measures analysis of variance
45

sis).
The steady state changes in MAP and HR Were ?tted to a

sigmoid logistic equation, plotted, and derivative of the equa
50

create curves that re?ect instantaneous change as Well as the

of hemorrhage for saline controls increased 6-fold to
88810.1 mmol/L, and four-fold for 5.5 mg/kg Delt-E treated
animals to 6541154 mmol/L. The 5.5 mg/kg Delt-E treated
group Was the only group that had a signi?cantly loWer lactic
acid level (p>0.01) than the saline control group.

With reference to FIG. 5, post hemorrhage injections of

BPSO, the MAP halfWay betWeen upper and loWer plateaus
(Flynn F W and Stricker 2003; Head and McCarty 1987,
McBride et al., 2005) Were employed. The average heart rate
gain, or slope of the curve betWeen the upper and loWer
in?ection points Was derived from coef?cients of the logistic

compared With saline.
With reference to FIG. 4, mean lactic acid levels at the end

With post hoc least square differences Were used (LSD analy

tion Were used to obtain the upper and loWer plateaus and

With reference to FIG. 2 and Table 1, repeated-measures
ANOVA revealed a signi?cant (P<0.01) increase in survival
time for the 2.9 mg/kg, 4.2 mg/kg, and 5.5 mg/kg Delt-E
treated group versus the control group (10711 min, 232114
min, and 331118 min vs. 5018 min, respectively.
With reference to FIG. 3, Delt-E did not signi?cantly alter
the average BP5O or average HR gain at the 5.5 mg/kg Delt-E
dose. The 5.5 mg/kg Delt-E dose is the most effective in

restoring hemodynamic parameters post hemorrhage When

(ANOVA) betWeen groups to identify differences betWeen
groups. To evaluate differences betWeen means, the ANOVA

27 1 7

(14.0 mg/kg)

end of 30 minutes, volume-controlled hemorrhage Was
induced folloWed by a post hemorrhage injection of 5.5
mg/kg Delt-E, the optimal dose found to increase hemody

Data Analysis: Statistical analysis Was preformed using

(4.2 mgkg)
(5.5 mgkg)

on MAP or HR occurred as a result of the pre-inj ection. At the

namic stability. Naltrexone (10 mg/kg, Sigma-Aldrich), NTB
(1 mg/kg, Sigma-Aldrich), and BNTX (1 mg/kg, Tocris Bio

Delt-E (6)
Delt-E (6)

group Were taken after venous catheter injection at a fre

quency of one every ?ve minutes for ?rst 30 minutes.

50 1 8

(1 mL/100
g control)

mined from arterial samples at the beginning of hemorrhage
(BOH) and 10 min after end of hemorrhage (EOH) and

Delt-E signi?cantly (P<0.01) increased pulse pressure
(mmHg systolic-mmHg diastolic) for the 2.9 mg/kg, 4.2
55

mg/kg, and 5.5 mg/kg Delt-E treated group versus the saline

equation and re?ects the greatest sensitivity of the barore?ex

control group (4210.37 mmHg, 4410.4 mmHg, and 4810.56
mmHg vs. 3810.44 mmHg respectively) in a dose dependent

(Head and McCarty 1987).

manner (P<0.01).

Results: The MAP at the beginning (11211.9 mmHg) or
end (3310.63 mmHg) of hemorrhage Was not signi?cantly
different betWeen any of the treatment groups using repeated

60

measures ANOVA. With reference to FIG. 1, the 5.5 mg/kg
Delt-E post treatment group Was signi?cantly (P<0.01)

higher When compared With the saline control group during
the entire interval examined. The 14.0 mg/kg dose of Delt-E
Was found to be toxic and thus is excluded from all ?gures as
seen in Table 1. With reference to FIG. 1 and Table 1, the max

65

With reference to FIG. 6, comparison of Delt-E mediated
survival time versus pH post hemorrhage shoWed a signi?cant
(R2:0.929) dose response correlation betWeen the decrease
in pH and increase in survival time. For every 0.1 decrease in
pH there is a 12.5 minute increase in survival time.

Naltrexone, the universal opioid antagonist of mu, kappa,
and 6 opioid receptors and the speci?c 62 receptor antagonist
NTB blocked the post hemorrhage hemodynamic recovery
bene?ts of 5.5 mg/kg Delt-E as seen in Table 2. BNTX the 61

US 7,705,119 B1
15

16

speci?c opioid antagonist, on the other hand, did not block the
5 .5 mg/kg Delt E improvement in survival and MAP recovery

dose response correlation between lactic acid concentration
and increased survival was found. It is possible that delta2

speci?c opioid receptor agonists such as Delt-E and Deltor

as seen in Table 2.

phin-DWm-am (Delt-Dvar) may induce a hibemation-like state
TABLE 2

of metabolic depression following severe hemorrhage,
thereby, retarding the anaerobic glycolytic pathway which is

Hemodynamic Biomarker Response to 30 minute Inhibitor Pre-treatment
ofInhibitors Before 5.5 mg/kg Delt-E Post Hemorrhage Iniection

known to be increased resulting in decreased levels of circu
lating lactate. Delt-E may also facilitate a cardioprotective

Group (11)

Survival Time

Maximum MAP

Maximum HR

recompensatory recovery mechanism following hemorrhage

(dose)

in minutes 1 SE.

in mmHg 1 SE.

in BPM 1 SE

50 1 8

35 1 9

425 1 94

which entails Delt-E’s pulse pressure. The greater the
increase in pulse pressure, the greater the survival. The role of
pulse pressure in ischemic stress response has not been fully
characterized. However, in humans it is known that exercise

58112

37113

423168

induced stress can alter pules pressure which increase stroke

95 1 11**

49 1 8*

419 1 75

volume and cardiac output leading to greater tissue perfusion.

56 1 10**

393 1 43

356 1 3**TT

55 112**

400 1 77

331 118**TT

58 1 7**

396 1 40

Saline (6)

(1 mL/100 g

control)
NTB(4)

(1 mg/kg)
Naltrexone (4)

Following injections of Delt-E there was a signi?cant
increase in pulse pressure with a dose related response lead

(10 Ing/kg)
Glibenclamide (4) 347 1 15**TT

(10 Ing/kg)
BNTX (4)

ing to greater tissue perfusion. Delt-E also dose dependently
enhanced MAP recovery and length of survival following

(1 mg/kg)
Delt-E (6)

20

(5.5 mg/kg)

controlled hemorrhage (Oeltgen et. al 2006).

J[TRats sacri?ced at six hours
*P < 0.05 compared with saline controls
**P < 0.01 compared with saline controls.
(n) = number of animals per treatment group

To further clarify the cellular mechanisms by which acti

vation of the 62 opioid receptor by Delt-E produces hemody
25

Legend: Repeated-measures ANOVA revealed no signi?cant differences
from controls when treatment with Naltrexone or Naltriben preceeded Delt E

intervention;. However, signi?cant differences in survival time and maxi
mum MAP similar to Delt E alone group were found when glibenclamide or

BNTX preceeded Delt E treatment. Therefore neither glibenclaminde nor
BNTX interfered with the Delt E advantage. No signi?cance difference was

30

seen in maximum BPM between any ofthe test groups. *P < 0.05. **P <
0.01.

Similarly, Glibenclamide did not alter the survival advan
tage of post treatment with Delt E since repeated-measures
ANOVA revealed no statistically signi?cant differences in
survival time distributions, and maximum MAP distributions
between the pre-treated Glibenclamide and Delt-E alone

channels. Their results demonstrated that the cardioprotective
35

40

gated K” channels and not to KATP channels (Wild et al.
1991). Our present results further demonstrated that the car

dioprotection provided by Delt-E, a 6 agonist, was not

blocked by Glibenclamide indicating that the hemodynamic
recovery protection is mediated by a mechanism not involv

ing KATP channels, but perhaps by a voltage-gated K” chan
45

increased survival time. The effects of speci?c opioid recep

nel.

The universal antagonist Naltrexone partially blocked the
hemodynamic recovery effects of Delt-E indicating that

tor sites activated by Delt-E were assessed by the response of

Naltrexone (a universal opioid receptor inhibitor) and BNTX
(a delta 1 speci?c opioid inhibitor) and NTB (a delta2 speci?c
opioid receptor inhibitor) on hemodynamic markers in

receptor subtype was linked to neuronal KA H, channels. How

ever, the cardioprotective effect of Deltorphin II, a 62 opioid
receptor agonist, was not blocked by Glibenclamide, which
demonstrates that the 62 receptor subtype is linked to voltage

Discussion: These studies demonstrated that Delt-E

protection, which included improvement in hemodynamic
stability markers including increased MAP, decreased HR,
increased pulse pressure (i.e. difference between systolic and
diastolic pressure), decreased plasma lactate production, and

namic recovery in rat, we studied the role of GM proteins and
the KATP channel in mediating this effect. It has been well
documented in several tissue types that the o-opioid receptor
is linked to K” channels via G proteins (Musser et al. 2004).
Wild et al. (1991) demonstrated that activation of the o-opioid
receptor via K” channels produced a cardioprotective effect
and the subtypes of this receptor were linked to different K”

effect produced by the ol-opioid receptor agonist DPDPE
could be negated by Glibenclamide, indicting that the 61

groups as seen in Table 2.

administration without accompanying ?uid resuscitation
immediately after severe hemorrhage resulted in ischemic

severe hemorrhage as had been previously demonstrated in
rats infused with Delt-Dvar24 hrprior to severe (53%) volume

Delt-E was acting upon a 6 opioid receptor. Further investi

gation with speci?c delta opioid receptor agonists (NTB (62)
50

and BNTX (61) revealed that only the 62 opioid receptor

severely hemorrhaged rats. The role of KATP channel activa

agonists NTB blocked Delt-E’s effect on shock and survival

tion was determined by the use of the non-speci?c KATP

following severe hemorrhage. Therefore, the site of action for
Delt-E is a 62 opioid receptor which, following intravenous
administration, promotes signi?cant recovery of hemody

channel blocker, Glibenclamide.
Post-hemorrhage treated controls (1 mL/ 100 g i.v. saline)
exhibited maximum MAP (i.e., 3519 mmHg), maximum HR
(i.e., 425194 bpm), lactic acid concentration of 8.910.12
mmol/L, and pulse pressure of38.310.44 mmHg. In contrast,
post-hemorrhage 5.5 mg/kg Delt-E treated rates exhibited
maximum MAP (5817 mmHg) and maximum HR (396140

bpm), lactic acid (6.511.2 mmol/L) and pulse pressure
(47.910.55 mmHg). At the 5.5 mg/kg dose Delt-E treated

55

tration after the occurrence of an event creating a risk of

circulatory and hypovolemic shock is an effective treatment.

The treatment provides protection against hemorrhage and
60

facilitates recovery.

Study Design: Prehemorrhage Delt-E Infusion

animals lived at least six times longer (331 minutes) versus

The hemorrhagic shock model used was a volume-con
trolled model similar to that of Summers et al. Acad Emerg

the saline control animals (50 minutes), P<0.01 signi?cance.

Using logistic analysis of MAP-HR gain suggests Delt-Eva,
did not signi?cantly alter the barore?ex sensitivity. However,
Delt-E facilitates a cardioprotective effect post-hemorrhage
through alternate pathways involving lactic acid reduction. A

namic biomarkers after severe hemorrhage.
The studies described herein indicate that Delt-E adminis

Med. 10:587-93 (2003). Twenty male Sprague-Dawley rats
65

(about 325-400 grams) were acclimated to a laboratory envi
ronment for a week, and then randomly assigned to one of two

groups, controls (n:14) and Delt-E treated group (n:5). In

